Q-omics provides the consensus-scored PROK2 profile across patient tissues and cancer cell-line models. PROK2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, PROK2 is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, PROK2 RNA expression shows 11,581 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight DLBC, LUSC, and PAAD as cancer lineages where PROK2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PROK2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PROK2 survival associations across molecular data types. PROK2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PROK2 RNA expression–survival associations across cancer types. High PROK2 expression shows unfavorable associations in DLBC, CESC, KIRP, LGG and KICH, but favorable associations in COAD. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify DLBC as the clearest survival context for PROK2 RNA expression.
This table summarizes PROK2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for PROK2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PROK2 shows lower tumor expression in LUSC, LUAD, LIHC, BRCA, KICH and KIRP. The LUSC box plot shows higher PROK2 RNA expression in normal versus tumor tissue (log2 FC = −1.383, t-test p < 0.001).
This table shows molecular features associated with PROK2 in patient tissues and cancer cell lines. In patient samples, PROK2 shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PROK2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BONE.
